交易 Capricor Therapeutics Inc - CAPR 差價合約

Capricor Therapeutics Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company advancing cell- and exosome-based therapies for cardiac and neuromuscular disorders. Its lead program, CAP-1002, is in late-stage trials for Duchenne muscular dystrophy (DMD), with potential for FDA breakthrough designation. The company also develops exosome-based platforms for RNA delivery. Capricor offers investors high-upside, development-stage exposure to regenerative medicine and orphan diseases.